Outcomes for patients with secondary CNS involvement in relapsed/refractory diffuse large B-cell lymphoma and estimation of eligibility for CAR T-cell therapy

Leuk Lymphoma. 2024 Apr;65(4):534-537. doi: 10.1080/10428194.2023.2296361. Epub 2023 Dec 22.

Sara Harrysson^{1

2}, Sandra Eloranta¹, Sara Ekberg¹, Gunilla Enblad³, Per-Ola Andersson⁴, Kristina Sonnevi², Maria Ljungqvist^{1

2}, Birgitta Sander⁵, Mats Jerkeman⁶, Karin E Smedby^{1

2}

¹ Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
² Department of Hematology, Karolinska University Hospital, Solna, Sweden.
³ Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
⁴ Department of Hematology and Coagulation, Sahlgrenska University Hospital, Gothenburg, and Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.
⁵ Division of Pathology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
⁶ Department of Oncology, Lund University, Lund, Sweden.

No abstract available

MeSH terms